Axxess Pharma is expecting to sign the exclusive license agreement within next 2 weeks.
The capsule is currently being sold by physicians, pharmacists and specialists in the US, and is expected to be made available in the name of Axxess Pharma in Canada and Middle East following Health Canada approval.
Gerald Sequeira, president and CEO of Axxess Pharma, said: “Our latest prescription cough and cold capsule is anticipated to generate strong global sales for our company. Customers and patients will no longer need to carry bottles of cough and cold medicine.
“The capsule is easy to carry; currently FDA approved and is soon to be approved by Health Canada. We are now in discussion to expand the FDA approved prescription capsule into Africa.”